These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

119 related items for PubMed ID: 11305233

  • 1. [Respiratory syncytial virus infection in high-risk infants].
    Adamovich K.
    Orv Hetil; 2001 Mar 18; 142(11):557-60. PubMed ID: 11305233
    [Abstract] [Full Text] [Related]

  • 2. The use of palivizumab monoclonal antibody to control an outbreak of respiratory syncytial virus infection in a special care baby unit.
    Cox RA, Rao P, Brandon-Cox C.
    J Hosp Infect; 2001 Jul 18; 48(3):186-92. PubMed ID: 11439005
    [Abstract] [Full Text] [Related]

  • 3. Incidence of respiratory syncytial virus-related hospitalizations in high-risk children: follow-up of a national cohort of infants treated with Palivizumab as RSV prophylaxis.
    Lacaze-Masmonteil T, Rozé JC, Fauroux B, French Pediatricians' Group of Sunagis Patients' Name-Based Programs.
    Pediatr Pulmonol; 2002 Sep 18; 34(3):181-8. PubMed ID: 12203846
    [Abstract] [Full Text] [Related]

  • 4. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants.
    Pedraz C, Carbonell-Estrany X, Figueras-Aloy J, Quero J, IRIS Study Group.
    Pediatr Infect Dis J; 2003 Sep 18; 22(9):823-7. PubMed ID: 14506376
    [Abstract] [Full Text] [Related]

  • 5. Use of palivizumab to control an outbreak of syncytial respiratory virus in a neonatal intensive care unit.
    Abadesso C, Almeida HI, Virella D, Carreiro MH, Machado MC.
    J Hosp Infect; 2004 Sep 18; 58(1):38-41. PubMed ID: 15350712
    [Abstract] [Full Text] [Related]

  • 6. Palivizumab: new indication. Moderate reduction in hospitalisation rate.
    Prescrire Int; 2004 Dec 18; 13(74):213-6. PubMed ID: 15612142
    [Abstract] [Full Text] [Related]

  • 7. Intravenous palivizumab and ribavirin combination for respiratory syncytial virus disease in high-risk pediatric patients.
    Chávez-Bueno S, Mejías A, Merryman RA, Ahmad N, Jafri HS, Ramilo O.
    Pediatr Infect Dis J; 2007 Dec 18; 26(12):1089-93. PubMed ID: 18043443
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Risk-Scoring Tool for respiratory syncytial virus prophylaxis in premature infants born at 33-35 completed weeks' gestational age in Canada.
    Paes B, Steele S, Janes M, Pinelli J.
    Curr Med Res Opin; 2009 Jul 18; 25(7):1585-91. PubMed ID: 19469698
    [Abstract] [Full Text] [Related]

  • 10. [Prevention of respiratory syncytial virus infection by SYNAGIS (palivizumab)].
    Pin I, Pilenko C, Bost M.
    Allerg Immunol (Paris); 2002 Dec 18; 34(10):371-4. PubMed ID: 12575622
    [Abstract] [Full Text] [Related]

  • 11. Palivizumab outcomes registry data from Spain: Infección Respiratoria Infantil por Virus Respiratorio Sincitial (IRIS) Study Group.
    Carbonell-Estrany X.
    Pediatr Infect Dis J; 2003 Feb 18; 22(2 Suppl):S55-7; discussion S57. PubMed ID: 12671453
    [Abstract] [Full Text] [Related]

  • 12. Experience with the use of palivizumab together with infection control measures to prevent respiratory syncytial virus outbreaks in neonatal intensive care units.
    Kurz H, Herbich K, Janata O, Sterniste W, Bauer K.
    J Hosp Infect; 2008 Nov 18; 70(3):246-52. PubMed ID: 18799241
    [Abstract] [Full Text] [Related]

  • 13. Hospital admission of high risk infants for respiratory syncytial virus infection: implications for palivizumab prophylaxis.
    Heikkinen T, Valkonen H, Lehtonen L, Vainionpää R, Ruuskanen O.
    Arch Dis Child Fetal Neonatal Ed; 2005 Jan 18; 90(1):F64-8. PubMed ID: 15613580
    [Abstract] [Full Text] [Related]

  • 14. Readmission with respiratory syncytial virus (RSV) infection among graduates from a neonatal intensive care unit.
    McCormick J, Tubman R.
    Pediatr Pulmonol; 2002 Oct 18; 34(4):262-6. PubMed ID: 12205567
    [Abstract] [Full Text] [Related]

  • 15. Palivizumab prophylaxis and hospitalization for respiratory syncytial virus disease in the Stockholm infant population, 1999 through 2002.
    Henckel E, Luthander J, Berggren E, Kapadia H, Naver L, Norman M, Bennet R, Eriksson M.
    Pediatr Infect Dis J; 2004 Jan 18; 23(1):27-31. PubMed ID: 14743042
    [Abstract] [Full Text] [Related]

  • 16. Beyond randomized controlled trials: a "real life" experience of respiratory syncytial virus infection prevention in infancy with and without palivizumab.
    Mitchell I, Tough S, Gillis L, Majaesic C.
    Pediatr Pulmonol; 2006 Dec 18; 41(12):1167-74. PubMed ID: 17058279
    [Abstract] [Full Text] [Related]

  • 17. [Treatment of infants with RSV infection: a retrospective analysis of the season 1998/99].
    Schauer U, Rieger CH.
    Klin Padiatr; 2002 Dec 18; 214(1):37-40. PubMed ID: 11823952
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Palivizumab prophylaxis of respiratory syncytial virus disease in 2000-2001: results from The Palivizumab Outcomes Registry.
    Parnes C, Guillermin J, Habersang R, Nicholes P, Chawla V, Kelly T, Fishbein J, McRae P, Goessler M, Gatti A, Calcagno JA, Eki C, Harris KA, Joyave J, McFarland K, Protter P, Sullivan M, Stanford A, Lovett N, Ortiz M, Rojas S, Cyrus S, Cyrus J, Cohen S, Buchin D, Riordan L, Zuniga M, Shah R, Minard C, Quintin A, Douglas G, van Houten J, Freutner S, Chartrand S, Nowatzke P, Romero J, Rhodes T, Benoit M, Walter E, Walker L, DeBonnett L, Cross M, Free T, Martin S, Shank K, Guedes B, Atkinson LA, Halpin GJ, Rouse K, Hand I, Geiss D, Marshall JR, Burleson L, Boland J, Seybold K, Hunter V, Unfer S, Schmucker J, Gley M, Marcus M, Thompson P, Milla P, Young C, Zanni R, Zinno V, Fetter-Zarzeka A, Busey A, Sokunbi MA, Airington S, Richard N, Muraligopal V, Lewis S, Weber FT, Giordano BP, Linehan D, Roach J, Davis R, Rzepka AA, Booth T, Smeltzer D, Walsh J, Arispe E, Rowley R, Bolling C, Botts T, Haskett K, Raby D, Batiz E, Gelfand A, Farrell L, Butler S, Colby L, Schochet P, Bentler J, Hirsch D, Wilkinson L, Aaronson A, Bennett E, Wingate J, Quinn D, Komendowski K, Deckard M, Frogel M, Nerwen C, Copenhaver S, Prater M, Wolsztein J, Mackey K, Benbow M, Naranjo M, Hensley S, Hayes C, Sadeghi H, Lawson SM, McCall M, Combs K, Ledbetter J, Sarnosky K, Swafford C, Speer M, Barton WJ, Mink JW, Lemm D, Hudak M, Case E, Rowen J, Fuentes S, Pane C, Richardson L, Chavarria C, Cassino D, Ghaffari K, Carroll C, Lee H, Guclu L, Johnson C, Blum V, Boron ML, Sorrentino M, Hirsch RL, Van Veldhuisen PC, Smith C, Palivizumab Outcomes Registry Study Group.
    Pediatr Pulmonol; 2003 Jun 18; 35(6):484-9. PubMed ID: 12746948
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.